| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5700754 | European Journal of Surgical Oncology (EJSO) | 2017 | 9 Pages |
Abstract
E1L3N appeared easier to use than SP142 to evaluate PD-L1 expression. A minority of EPMM expressed PD-L1, and only a few cells were positive. PD-L1 expression by immune cells evaluated with E1L3N was an independent prognostic factor in EPMM.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
S. Valmary-Degano, P. Colpart, L. Villeneuve, F. Monnien, L. M'Hamdi, G. Lang Averous, M. Capovilla, F. Bibeau, M.-H. Laverriere, V. Verriele-Beurrier, H. Ben Rejeb, P. Dartigues, J. Hommell-Fontaine, F.-N. Gilly, S. Isaac, E. Mery,